2023 Was a troublesome 12 months for your biopharma marketplace, with a number of firms downsizing and restructuring their workforces to remain afloat. You will find signs of recovery, as mergers and acquisitions picked up throughout the pharmaceutical and daily life sciences marketplace in the latter A part of 2023 https://sites.google.com/view/bio-sites/blog